Nov. 3, 2015
Researchers at the University of Nebraska—Lincoln have identified small molecules targeting UGDH, a novel biomarker of prostate cancer.
Prostate Cancer (PC) is commonly treated with androgen deprivation therapy (ADT), but tumors may become resistant to androgen removal and are then categorized as Castration-Resistant PC (CRPC). The enzyme UDP-Glucose Dehydrogenase (UGDH) is involved in the generation of precursors that drive removal of androgens. This technology describes the use of UGDH as a novel therapeutic target for prostate cancer (PC). Utilizing a high throughput compound screen, small molecule inhibitors of UGDH activity were identified. This is closely related to our Tech #2302 , where the inventors identified UGDH as a novel prognostic indicator of PC.
The inhibition of UGDH activity via small molecules will alter the metabolic flux of androgens in PC cells, control tumor growth, and potentially improve patient outcomes.
Potential therapeutics for prostate cancer patients who are likely to fail androgen deprivation therapy
• Novel target for prostate cancer treatment
• A companion diagnostic ( Tech 2302 ) is available
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
enzyme udp-glucose dehydrogenase
control tumor growth
androgen deprivation therapy
small molecule inhibitors
inventors identified ugdh
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium